Protocol Ledger

NCT06159673 · Phase II/III · RECRUITING

ACP-204 in Adults With Alzheimer's Disease Psychosis

Interventional Phase II/III clinical trial protocol NCT06159673 sponsored by ACADIA Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-14 Enrollment: 1,074 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06159673
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,074 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06159673
Protocol FieldVerified Registry Value
NCT IdentifierNCT06159673
Consolidated Lead SponsorACADIA Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,074 participants (ESTIMATED)
Registered Start Date2023-11-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06159673
Hospital Research SiteLocationSite Profile
Advanced Research Center, Inc.Anaheim, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI